Theriva Biologics, Inc. (TOVX)

US — Healthcare Sector
Peers: GLMD  BIVI  NKGN  ELAB  MLEC  ISPC  WINT  BCTXZ  CMMB  CARM 

Automate Your Wheel Strategy on TOVX

With Tiblio's Option Bot, you can configure your own wheel strategy including TOVX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol TOVX
  • Rev/Share 0.0228
  • Book/Share 1.5731
  • PB 0.1894
  • Debt/Equity 0.1179
  • CurrentRatio 1.1895
  • ROIC -0.8656

 

  • MktCap 2859667.0
  • FreeCF/Share -2.6785
  • PFCF -0.1581
  • PE -0.0681
  • Debt/Assets 0.0349
  • DivYield 0
  • ROE -1.6932

 

  • Rating B-
  • Score 3
  • Recommendation Neutral
  • P/E Score 1
  • DCF Score 5
  • P/B Score 5
  • D/E Score 2

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

Theriva Biologics Provides Response to Unusual Market Action
TOVX
Published: October 24, 2025 by: GlobeNewsWire
Sentiment: Neutral

ROCKVILLE, Md., Oct. 24, 2025 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American: TOVX), (“Theriva” or the “Company”), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, announced today that the Company had become aware of unusual trading activity in its common stock on the NYSE American (the “NYSE”) on October 24, 2025. The Company is issuing this press release pursuant to Section 401(d) of the NYSE Company Guide. The Company has made inquiries and does not believe corrective actions are appropriate. The Company is further announcing that there has been …

Read More
image for news Theriva Biologics Provides Response to Unusual Market Action
Theriva™ Biologics Reports Second Quarter 2025 Operational Highlights and Financial Results
TOVX
Published: August 11, 2025 by: GlobeNewsWire
Sentiment: Neutral

- Released positive topline data from the VIRAGE Phase 2b study of VCN-01 (zabilugene almadenorepvec); expanded data to be presented at the European Society for Medical Oncology (ESMO) 2025 Congress in October -

Read More
image for news Theriva™ Biologics Reports Second Quarter 2025 Operational Highlights and Financial Results

About Theriva Biologics, Inc. (TOVX)

  • IPO Date 2006-12-18
  • Website https://therivabio.com
  • Industry Biotechnology
  • CEO Steven A. Shallcross CPA
  • Employees 20
Theriva Biologics Inc., a clinical-stage company, develops therapeutics to treat diseases in areas of high unmet need. The company's lead product candidates include SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases. It also develops VCN-01 for the treatment of patients with pancreatic cancer, head and neck squamous cell carcinoma, colorectal cancer, and retinoblastoma. In addition, the company develops clinical stage products, such as SYN-006 to prevent aGVHD and infection by carbapenem resistant enterococci; SYN-007 for preventing antibiotic associated diarrhea with oral ß-lactam antibiotics; SYN-005 for the prevention and treatment of pertussis; and VCN-11 to treat cancer. It has collaborations with Intrexon Corporation, The University of Texas at Austin, and Cedars-Sinai Medical Center; and a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. The company was formerly known as Synthetic Biologics, Inc. and changed its name to Theriva Biologics Inc. in October 2022. Theriva Biologics Inc. is headquartered in Rockville, Maryland.